# SEC

SECURITIES AN	ND EXCHANGE CO	MMISSION
	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
PURSUA	NT TO SECTION 13 OR 15(d) (	<b>)</b> F
THE SECU	RITIES EXCHANGE ACT OF	1934
Date of Report (I	Date of Earliest Event Reported): May 1	10, 2004
	MACEUTICALS CO	RPORATION
Massachusetts (State or other jurisdiction	0-10824 (Commission File Number)	04-2297484 (I.R.S. Employer
of incorporation)		<b>Identification Number</b> )
	100 Beaver Street	

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

 $(Registrant\ \ s\ telephone\ number,\ including\ area\ code)$ 

#### ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

		hit	

99.1 Press Release issued by Oscient Pharmaceuticals Corporation on May 10, 2004.

#### ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On May 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2003. A copy of that press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By: /s/ Stephen Cohen

Name: Stephen Cohen

Title: Senior Vice President and Chief Financial Officer

Date: May 14, 2004

### EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by Oscient Pharmaceuticals Corporation on May 10, 2004.